WO2008145323A1 - Pharmaceutical formulation for interferons - Google Patents

Pharmaceutical formulation for interferons Download PDF

Info

Publication number
WO2008145323A1
WO2008145323A1 PCT/EP2008/004165 EP2008004165W WO2008145323A1 WO 2008145323 A1 WO2008145323 A1 WO 2008145323A1 EP 2008004165 W EP2008004165 W EP 2008004165W WO 2008145323 A1 WO2008145323 A1 WO 2008145323A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
interferon alpha
present
concentration
methionine
Prior art date
Application number
PCT/EP2008/004165
Other languages
French (fr)
Inventor
Astrid Pappenberger
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of WO2008145323A1 publication Critical patent/WO2008145323A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to a pharmaceutical formulation comprising interferon alpha (IFN ⁇ ) as active agent and an anti-oxidant.
  • IFN ⁇ interferon alpha
  • Interferons are naturally occurring proteins which have antiviral, antiproliferative and immunoregulatory activity.
  • the interferon alpha family (INF ⁇ ) represents the predominant class of IFNs produced by stimulated peripheral blood lymphocytes.
  • IFN ⁇ has therapeutic potential in a wide range of viral diseases, such as hepatitis B and hepatitis C, as well as proliferative disorders such as chronic myelogenous leukemia.
  • IFN ⁇ is used in two forms in therapeutical applications: native (unmodified) IFN ⁇ and modified IFN ⁇ .
  • One modification is the attachment of one or more polyethylenglycols (PEG) to IFN ⁇ .
  • PEG polyethylenglycols
  • Pegylated IFN ⁇ (PEG- IFN ⁇ ) shows improved pharmacokinetic properties compared to unmodified IFN ⁇ .
  • EP 0 736 303 discloses an aqueous human serum free IFN ⁇ solution comprising
  • IFN ⁇ a non-ionic detergent
  • a buffer for adjusting pH to 4.5 - 5.5 a buffer for adjusting pH to 4.5 - 5.5 and benzyl alcohol.
  • WO 04/096263 discloses a human serum free pharmaceutical composition for unmodified interferon beta (IFN ⁇ ) comprising methionine as antioxidant.
  • IFN ⁇ interferon beta
  • the antioxidant is present at a concentration of about 2mM to about 75 mM. In a more preferred embodiment, the antioxidant is methionine and is present at a concentration of about 2 mM to about 50 mM. In a further preferred
  • the methionine is present in a concentration of about 2 mM to about 25 mM, even more preferably 2 mM to about 10 mM.
  • the pharmaceutical formulation comprises a surfactant.
  • the surfactant is preferably selected from the group of polyethylen-sorbitan esters, more preferably a polyethylen-sorbitan -polyethylen(20) -sorbitan ester.
  • the surfactant is preferably present in an amount of about 0.001 - 0.05%.
  • the pharmaceutical formulation comprises a buffer, preferably an acetate buffer of pH 4.0 to 6.5.
  • the pharmaceutical formulation comprises an isotonic agent. More preferably, this may comprise excipients for the groups such as salts, for example sodium chloride, sugars or sugar alcohols, such as sucrose, trehalose or amino acids, such as glycine, arginine or other excipients used for parenteral purposes, for example EDTA.
  • excipients for the groups such as salts, for example sodium chloride, sugars or sugar alcohols, such as sucrose, trehalose or amino acids, such as glycine, arginine or other excipients used for parenteral purposes, for example EDTA.
  • the interferon alpha is present at a concentration of about 0.01 mg/ml to about 10 mg/ml.
  • the interferon alpha is an interferon alpha conjugate, more preferably a PEG interferon alpha conjugate, even more preferably a monopegylated interferon alpha conjugate.
  • Methods for protein pegylation are well known to a person skilled in the art and are for example disclosed in EP 0 809 996 and US 5,122,614 which are herein incorporated by reference.
  • the interferon alpha is an interferon alpha 2a.
  • the interferon is selected from the interferon molecules disclosed in WO 2005/113592 and WO 2004/046365 which are incorporated herein by reference.
  • the interferon molecule has the amino acid sequence of Seq. Id. No. 1.
  • the present invention is directed to the use of a pharmaceutical formulation of the present invention for the manufacture of a medicament for the treatment of hepatitis C infections.
  • the medicament is for the treatment of a chronic hepatitis C infection, more preferably for the treatment of a chronic hepatitis C infection caused by hepatitic C virus having genotype 1.
  • the formulation of the present invention is especially suitable for the storage of IFN ⁇ in vials, pref ⁇ lled syringes, ampoules, cartridges, etc.
  • the formulation of the present invention can be used to stably store the protein IFN ⁇ at different temperatures, including frozen storage, storage under refrigerated conditions or at room temperature for given periods of time.
  • Figure 1 shows the results of a 4 week stability test for IFN ⁇ formulations measuring oxidation
  • Figure 2 shows the results of a 4 week stability test for IFN ⁇ formulations measuring aggregate formation.
  • Stability tests for 4 formulations were performed to assess the effect of the pharmaceutical formulations of the present invention on oxidation and aggregation of IFN ⁇ .
  • Stability tests a pegylated IFN ⁇ molecule having Seq. Id. No. 1 was used.
  • the tested pharmaceutical formulations contained the following anti-oxidants and concentrations:
  • F3 contains 1OmM methionine as anti-oxidant
  • F4 contains 2mg/ml benzylalcohol as anti-oxidant and was used to assess the effect of benzylalcohol at a low concentration.
  • the formulations Fl - F4 were stored for 4 weeks at 5°C, 25 0 C and 40 0 C. After 4 weeks storage at the given temperatures, the oxidation of the IFN ⁇ molecules in the formulations was measured. The results are graphically depicted in Figure 1. Significant oxidation occurs after 4 weeks storage at 40 0 C in absence of antioxidants. Addition of methionine (for example 2mM and 1OmM) or benzylalcohol (for example 2mg/ml) prevents oxidation.
  • methionine for example 2mM and 1OmM
  • benzylalcohol for example 2mg/ml

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical formulation comprising interferon alpha (IFNα) as active agent and an antioxidant.

Description

Case 24273
PHARMACEUTICAL FORMULATION FOR INTERFERONS
The present invention relates to a pharmaceutical formulation comprising interferon alpha (IFNα) as active agent and an anti-oxidant.
Interferons (IFN) are naturally occurring proteins which have antiviral, antiproliferative and immunoregulatory activity. The interferon alpha family (INFα) represents the predominant class of IFNs produced by stimulated peripheral blood lymphocytes.
IFNα has therapeutic potential in a wide range of viral diseases, such as hepatitis B and hepatitis C, as well as proliferative disorders such as chronic myelogenous leukemia.
IFNα is used in two forms in therapeutical applications: native (unmodified) IFNα and modified IFNα. One modification is the attachment of one or more polyethylenglycols (PEG) to IFNα. Pegylated IFNα (PEG- IFNα ) shows improved pharmacokinetic properties compared to unmodified IFNα.
One problem recognized in connection with formulation of interferons into pharmaceutical products is aggregation of the interferon polypeptides.
EP 0 736 303 discloses an aqueous human serum free IFNα solution comprising
IFNα, a non-ionic detergent, a buffer for adjusting pH to 4.5 - 5.5 and benzyl alcohol.
WO 04/096263 discloses a human serum free pharmaceutical composition for unmodified interferon beta (IFNβ) comprising methionine as antioxidant.
Therefore, there is a need for a pharmaceutical formulation for IFNα or pegylated forms thereof, which leads to an increased molecule stability and reduced aggregation of IFNα.
It is an object of the present invention to provide a pharmaceutical formulation comprising IFNα as active agent and an antioxidant.
In a preferred embodiment, the antioxidant is present at a concentration of about 2mM to about 75 mM. In a more preferred embodiment, the antioxidant is methionine and is present at a concentration of about 2 mM to about 50 mM. In a further preferred
KP/ 17.03.2008 embodiment, the methionine is present in a concentration of about 2 mM to about 25 mM, even more preferably 2 mM to about 10 mM.
In a further preferred embodiment, the pharmaceutical formulation comprises a surfactant. The surfactant is preferably selected from the group of polyethylen-sorbitan esters, more preferably a polyethylen-sorbitan -polyethylen(20) -sorbitan ester. The surfactant is preferably present in an amount of about 0.001 - 0.05%.
In a further preferred embodiment, the pharmaceutical formulation comprises a buffer, preferably an acetate buffer of pH 4.0 to 6.5.
In a further preferred embodiment, the pharmaceutical formulation comprises an isotonic agent. More preferably, this may comprise excipients for the groups such as salts, for example sodium chloride, sugars or sugar alcohols, such as sucrose, trehalose or amino acids, such as glycine, arginine or other excipients used for parenteral purposes, for example EDTA.
In a further preferred embodiment, the interferon alpha is present at a concentration of about 0.01 mg/ml to about 10 mg/ml.
In a further preferred embodiment, the interferon alpha is an interferon alpha conjugate, more preferably a PEG interferon alpha conjugate, even more preferably a monopegylated interferon alpha conjugate. Methods for protein pegylation are well known to a person skilled in the art and are for example disclosed in EP 0 809 996 and US 5,122,614 which are herein incorporated by reference.
In a further preferred embodiment, the interferon alpha is an interferon alpha 2a.
In a further preferred embodiment, the interferon is selected from the interferon molecules disclosed in WO 2005/113592 and WO 2004/046365 which are incorporated herein by reference.
In a much preferred embodiment, the interferon molecule has the amino acid sequence of Seq. Id. No. 1.
In a second object, the present invention is directed to the use of a pharmaceutical formulation of the present invention for the manufacture of a medicament for the treatment of hepatitis C infections.
In a preferred embodiment the medicament is for the treatment of a chronic hepatitis C infection, more preferably for the treatment of a chronic hepatitis C infection caused by hepatitic C virus having genotype 1. The formulation of the present invention is especially suitable for the storage of IFNα in vials, prefϊlled syringes, ampoules, cartridges, etc.
The formulation of the present invention can be used to stably store the protein IFNα at different temperatures, including frozen storage, storage under refrigerated conditions or at room temperature for given periods of time.
Short description of the drawings
Figure 1 shows the results of a 4 week stability test for IFNα formulations measuring oxidation and
Figure 2 shows the results of a 4 week stability test for IFNα formulations measuring aggregate formation.
Stability tests for 4 formulations were performed to assess the effect of the pharmaceutical formulations of the present invention on oxidation and aggregation of IFNα. In the stability tests a pegylated IFNα molecule having Seq. Id. No. 1 was used.
The tested pharmaceutical formulations contained the following anti-oxidants and concentrations:
• Fl contains no antioxidant and was used as control, • F2 contains 2mM methionine as anti-oxidant,
• F3 contains 1OmM methionine as anti-oxidant,
• F4 contains 2mg/ml benzylalcohol as anti-oxidant and was used to assess the effect of benzylalcohol at a low concentration.
The formulations Fl - F4 were stored for 4 weeks at 5°C, 25 0C and 40 0C. After 4 weeks storage at the given temperatures, the oxidation of the IFNα molecules in the formulations was measured. The results are graphically depicted in Figure 1. Significant oxidation occurs after 4 weeks storage at 400C in absence of antioxidants. Addition of methionine (for example 2mM and 1OmM) or benzylalcohol (for example 2mg/ml) prevents oxidation.
The results graphically depicted in Figure 2 stem from a stability test performed as described above but instead of measuring oxidation after 4 weeks storage, aggregate formation was determined. Under accelerated conditions (400C), formation of aggregates is observed in the absence of antioxidant (17%). Addition of methionine (both concentrations) or benzylalcohol (2mg/ml) leads to a significant reduction in aggregation.
While there are shown and described presently preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited thereto but may be otherwise variously embodied and practiced within the scope of the following claims.

Claims

Claims
1. A pharmaceutical formulation comprising an interferon alpha as active agent and an anti-oxidant.
2. The pharmaceutical formulation of claim 1, wherein the antioxidant is present at a concentration of about 2mM to about 75 mM.
3. The pharmaceutical formulation of claim 1 or 2, wherein the antioxidant is methionine.
4. The pharmaceutical formulation of claim 3, wherein the methionine is present at a concentration of about 2mM to about 75 mM.
5. The pharmaceutical formulation of claim 4, wherein the methionine is present at a concentration of about 2 mM to about 50 mM.
6. The pharmaceutical formulation of claim 5, wherein the methionine is present at a concentration of 2 mM to about 25 mM.
7. The pharmaceutical formulation of claim 6, wherein the methionine is present at a concentration of about 2 mM to about 10 mM.
8. The pharmaceutical formulation of one of the preceding claims, wherein it further comprises a surfactant.
9. The pharmaceutical formulation of claim 8, wherein the surfactant is selected from the group of polyethylen-sorbitan esters.
10. The pharmaceutical formulation of claim 9, wherein the surfactant is preferably a polyethylen-sorbitan -polyethylen(20) -sorbitan ester.
11. The pharmaceutical formulation of claims 8 to 10, wherein the surfactant is present in an amount of about 0.001 - 0.05 %.
12. The pharmaceutical formulation of one of the preceding claims, wherein it further comprises a buffer, preferably an acetate buffer of pH 4.0 to 6.5.
13. The pharmaceutical formulation of claim 12, wherein it comprises an acetate buffer of pH 5.5 to 6.5.
14. The pharmaceutical formulation of one of the preceding claims, wherein it further comprises an isotonic agent, preferably a salt, a sugar or a sugar alcohol.
15. The pharmaceutical formulation of claim 14, wherein the salt is preferably sodium chloride.
16. The pharmaceutical formulation of one of the preceding claims, wherein it further comprises an isotonic agent, preferably an amino acid.
17. The pharmaceutical formulation of any one of the preceding claims, wherein the interferon alpha is present at a concentration of about 0.01 mg/ml to about 5 mg/ml.
18. The pharmaceutical formulation of claim 17, wherein the interferon alpha is present at a concentration of about 0.05 mg/ml to about 0.1 mg/ml.
19. The pharmaceutical formulation of one of the preceding claims, wherein it further comprises EDTA.
20. The pharmaceutical formulation of any one the preceding claims, wherein the interferon alpha is an interferon alpha conjugate, preferably a PEG interferon alpha conjugate.
21. The pharmaceutical formulation of claim 20, wherein the pegylated interferon alpha conjugate is a monopegylated interferon alpha conjugate.
22. The pharmaceutical formulation of any one of the preceding claims, wherein the interferon alpha is an interferon alpha 2a.
23. The pharmaceutical formulation of any one of the preceding claims, wherein the interferon has the amino acid sequence of Seq. Id. No. 1.
24. Use of a pharmaceutical formulation of claims 1 to 23 for the manufacture of a medicament for the treatment of hepatitis C infections.
25. The use of claim 24, wherein the hepatitis C infection is a chronic hepatitis C infection.
26. The use of claim 24 or 25, wherein the hepatitis C infection is a hepatitis C genotype 1 infection.
PCT/EP2008/004165 2007-05-31 2008-05-26 Pharmaceutical formulation for interferons WO2008145323A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109262.1 2007-05-31
EP07109262 2007-05-31

Publications (1)

Publication Number Publication Date
WO2008145323A1 true WO2008145323A1 (en) 2008-12-04

Family

ID=39758852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004165 WO2008145323A1 (en) 2007-05-31 2008-05-26 Pharmaceutical formulation for interferons

Country Status (1)

Country Link
WO (1) WO2008145323A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077402A2 (en) 2009-12-23 2011-06-30 Flamel Technologies Amphiphilic polymer functionalised by methionine
WO2016046101A1 (en) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9644017B2 (en) 2008-01-09 2017-05-09 Sanofi-Aventis Deutschland Gmbh Insulin derivatives having an extremely delayed time-action profile
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
EP0736303A2 (en) * 1995-04-06 1996-10-09 F. Hoffmann-La Roche Ag Interferon solution
WO2005069758A2 (en) * 2004-01-09 2005-08-04 Alza Corporation Frequency assisted transdermal agent delivery method and system
US20070059285A1 (en) * 2003-05-01 2007-03-15 Ares Trading S.A. Human serum albumin-free stabilized interferon liquid formulations
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
EP0736303A2 (en) * 1995-04-06 1996-10-09 F. Hoffmann-La Roche Ag Interferon solution
US20070059285A1 (en) * 2003-05-01 2007-03-15 Ares Trading S.A. Human serum albumin-free stabilized interferon liquid formulations
WO2005069758A2 (en) * 2004-01-09 2005-08-04 Alza Corporation Frequency assisted transdermal agent delivery method and system
WO2007095288A2 (en) * 2006-02-13 2007-08-23 Nektar Therapeutics Methionine-containing protein or peptide compositions and methods of making and using

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9644017B2 (en) 2008-01-09 2017-05-09 Sanofi-Aventis Deutschland Gmbh Insulin derivatives having an extremely delayed time-action profile
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
WO2011077402A2 (en) 2009-12-23 2011-06-30 Flamel Technologies Amphiphilic polymer functionalised by methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP2017528526A (en) * 2014-09-23 2017-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Stable benzyl alcohol-free aqueous solution containing α-type interferon
CN107073080A (en) * 2014-09-23 2017-08-18 豪夫迈·罗氏有限公司 The aqueous solution preparation without benzylalcohol of stabilization comprising alpha-interferon
WO2016046101A1 (en) * 2014-09-23 2016-03-31 F. Hoffmann-La Roche Ag Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Similar Documents

Publication Publication Date Title
WO2008145323A1 (en) Pharmaceutical formulation for interferons
JP5346065B2 (en) Stable interferon liquid formulation without HSA
ES2418833T3 (en) Stabilized interferon liquid formulations
PL211886B1 (en) Stabilized liquid polypeptide-containing pharmaceutical compositions
US8932574B2 (en) Stable liquid interferon beta formulations
EA002754B1 (en) Stable liquid interferon formulations
JP2001517635A (en) Interferon-β liquid composition
EP0697887A1 (en) Stable liquid compositions of gamma interferon
CA2888442A1 (en) Stable pharmaceutical composition of peginterferon alpha-2b
WO2008066322A1 (en) A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta
JP3479082B2 (en) Thrombopoietin composition
JP2008050320A (en) INTERFERON-beta-CONTAINING MEDICINAL COMPOSITION
JP2013543872A (en) Composition for stably storing interferon-β
US20170360891A1 (en) Stable, Benzyl Alcohol-free Aqueous Solution Formulations Containing Alpha-type Interferon
WO2007034509A2 (en) Recombinant granulocyte-colony stimulating factor formulation and process
LT4947B (en) Alfa interferon pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08758754

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08758754

Country of ref document: EP

Kind code of ref document: A1